SCHEMBL1776371

SCHEMBL1776371

CO[C@@H]1C[C@@H](OCc2ccccc2)[C@H](O)[C@@H](CO)O1

nearest known ligand 0.51

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
PDE4D Q08499 3/20 0.51
SLC6A2 P23975 2/20 0.47
LGALS8 O00214 1/20 0.44
PSEN1 P49768 1/20 0.40
PSEN2 P49810 1/20 0.40
APH1B Q8WW43 1/20 0.40
NCSTN Q92542 1/20 0.40
APH1A Q96BI3 1/20 0.40
PSENEN Q9NZ42 1/20 0.40
TSHR P16473 1/20 0.39
CYP2C19 P33261 1/20 0.39
ADORA2A P29274 3/20 0.38
GYPA P02724 1/20 0.38
ADORA1 P30542 1/20 0.38
OGA O60502 1/20 0.38
HRAS P01112 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10755807 1.00 PDE4D (0.51) PDE4DSLC6A2LGALS8PSEN1PSEN2
SCHEMBL10755806 1.00 PDE4D (0.51) PDE4DSLC6A2LGALS8PSEN1PSEN2
SCHEMBL1776370 1.00 PDE4D (0.51) PDE4DSLC6A2LGALS8PSEN1PSEN2
SCHEMBL1776369 1.00 PDE4D (0.51) PDE4DSLC6A2LGALS8PSEN1PSEN2
SCHEMBL10807993 0.91 PDE4D (0.54) PDE4DSLC6A2LGALS8PSEN1PSEN2
SCHEMBL19891704 0.88 PDE4D (0.49) PDE4DSLC6A2PSEN1PSEN2APH1B
SCHEMBL7909402 0.84 PDE4D (0.42) PDE4DSLC6A2PSEN1PSEN2APH1B
SCHEMBL10904817 0.84 PDE4D (0.55) PDE4DSLC6A2TSHRCYP2C19ADORA2A
SCHEMBL6451122 0.84 PDE4D (0.55) PDE4DSLC6A2TSHRCYP2C19ADORA2A
SCHEMBL10904820 0.84 PDE4D (0.55) PDE4DSLC6A2TSHRCYP2C19ADORA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7943584-B2 Medicinal composition containing diabetes remedy SANKYO COMPANY, LIMITED (JP) 2011-05-17 US disclosed
EP-1589023-B1 OLIGOSACCHARIDE DERIVATIVE DAIICHI SANKYO CO LTD (JP) 2010-08-25 EP disclosed
US-7632930-B2 Oligosaccharide derivative SANKYO COMPANY LIMITED (JP) 2009-12-15 US disclosed
US-20080194495-A1 Oligosaccharide Derivative HONDA TAKESHI 2008-08-14 US disclosed
US-7361744-B2 Oligosaccharide derivative SANKYO COMPANY LIMITED (JP) 2008-04-22 US disclosed
US-20080039367-A1 Medicinal Composition Containing Diabeted Remedy SANKYO COMPANY, LIMITED (JP) 2008-02-14 US disclosed
EP-1792620-A1 MEDICINAL COMPOSITION CONTAINING DIABETES REMEDY Sankyo Company, Limited (JP) 2007-06-06 EP disclosed
US-20060025350-A1 Oligosaccharide derivative SANKYO COMPANY, LIMITED (JP) 2006-02-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080039367-A1 Medicinal Composition Containing Diabeted Remedy DPP4, IAPP, AMY2A PDE4D 105/4885SLC6A2 2459/4885LGALS8 651/4885
US-20060025350-A1 Oligosaccharide derivative MAN1B1, FUT6, MAN2A1 PDE4D 1699/4885SLC6A2 4529/4885LGALS8 171/4885
US-20080194495-A1 Oligosaccharide Derivative MAN1B1, FUT6, MAN2A1 PDE4D 1699/4885SLC6A2 4529/4885LGALS8 171/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.